
|Articles|October 8, 2021
In case you missed it: Oct. 4 to Oct. 8
Here's what you missed this week.
Advertisement
This week's top articles included:
Alyssa Dweck, MD, on menopause products, her podcast, and more from NAMS 2021
Are you seeing a rise in STI cases?
Women with endometriosis have greater psychological and sexual distress, study finds
Brooke Faught, NP on sexual health, trauma-informed care, and the perks of meeting in-person
NFID 2020-2021 flu season survey results show pregnant women remain unprotected
Advertisement
Related to this article

Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.

Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.

Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.

Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.

A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.

Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.

The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Reactions to FDA's boxed warning removals for menopausal hormone therapy
2
Top headlines in women's health from October 2026
3
Top video interviews from The Menopause Society 2026 Annual Meeting
4
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
5

